Beschreibung:
Recently, the microbiome was associated with hallmark features of pancreatic ductal adenocarcinoma (PDAC). This dismal human disease with one of the lowest survival rates of below 10% is characterized by clinical challenges such as unspecific symptoms, lack of biomarkers, late diagnosis, refractoriness against systemic therapies, and a high recurrence rate after surgery. The biology behind these difficulties has been approached in multiple ways, for instance by tackling the pronounced desmoplastic stroma or investigating chemotherapy-inactivating enzymes. To date, no significant progress wi...